2种多西他赛联合表柔比星方案新辅助化疗乳腺癌疗效与安全性的比较

Comparison of the Efficacy and Safety of 2 Regimens of Taxotere Combined with Epirubicin in the Neoadjuvant Chemotherapy of Breast Cancer

目的;观察2种多西他赛联合表柔比星方案新辅助化疗乳腺癌的近期疗效和毒副反应。方法：78例局部晚期乳腺癌患者随机分为TEC组（45例）和TE组（33例）。TEC组患者给予多西他赛注射液75 mg/m^2,静脉滴注,d1＋注射用盐酸表柔比星60 mg/m^2,静脉滴注,d1＋注射用环磷酰胺500 mg/m^2,静脉推注,d1;TE组患者给予多西他赛注射液＋注射用盐酸表柔比星（用法用量同TEC组）。两组患者均治疗21 d为1个周期,共4~6个周期。所有患者完成至少4个周期后评价疗效和毒副反应,并随访6个月生存率。结果：两组患者的近期疗效、毒副反应、生存率比较,差异均无统计学意义（P〉0.05）。结论 ：TEC和TE方案治疗乳腺癌的近期疗效和安全性均相当,均可作为新辅助化疗的辅助药物。

OBJECTIVE ： To observe the short-term efficacy and toxicity reaction of 2 regimens of taxotere combined with epirubicin in the neoadjuvant chemotherapy of breast cancer. METHODS ： 78 patients with locally advanced breast cancer were randomly divided into TEC group （45 cases） and TE group （33 cases）. TEC group was treated with taxotere 75 mg/m^2 by intravenous injection, d1＋epirubicin 60 mg/m^2 by intravenous injection, d1＋cyclophosphamide 500 mg/m^2 by intravenous injection dl. TE group was treated with taxotere 75 mg/m^2 by intravenous injection, d1＋epirubicin 60 mg/m^2 by intravenous injection, d1. 21 days were a treatment course for 2 groups, and there were totally 4-6 courses. In the 2 groups, efficacy and toxicity reaction were evaluated af- ter 4 weeks at least, and survival rate of 6 months was followed-up. RESULTS： The differences were not statistically significant in the short-term efficacy and toxicity reaction and survival rate between 2 groups （P〉0.05）. CONCLUSIONS： TEC and TC have similar short-term efficacy and safety in the treatment of locally advanced breast cancer. Both of them can be used as adjuvant medicines for neoadjuvant chemotherapy.